When using the pharmacological inhibitor of Klf-5, ML264, an improvement in echocardiographic parameters, such as ejection fraction, was observed, as well as a reduction in end-diastolic and systolic volume, exerting a protective effect against ischemic cardiomyopathy [78]. Here, KLF5 is linked to ischemic cardiomyopathy.